Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

CANbridge gets rights to Aveo's mAb AV203; deal terminated

Executive Summary

Aveo Pharmaceuticals Inc. (also known as Aveo Oncology) granted CANbridge Life Sciences Ltd. exclusive rights to develop and sell its anticancer monoclonal antibody AV203 worldwide excluding the US, Canada, and Mexico. Biogen Idec previously held an option to the project under a 2009 deal, but waived its option in 2014.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies